Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.03), Fidelity Earnings reports. The firm had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 20.67% and a negative net margin of 8,193.08%.
Shares of AUPH traded down $0.08 during trading hours on Friday, reaching $5.37. 379,689 shares of the company traded hands, compared to its average volume of 405,089. The firm has a market capitalization of $451.96 million, a PE ratio of -5.84 and a beta of 2.18. Aurinia Pharmaceuticals has a 12-month low of $4.41 and a 12-month high of $7.60.
A number of equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 16th. Cantor Fitzgerald set a $16.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 16th. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $10.89.
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.